Getting your player ready...
Two subsidiaries of pharmaceutical giant Johnson & Johnson have agreed to pay more than $81 million stemming from allegedly illegal promotion of the epilepsy drug Topamax for psychiatric uses, the Justice Department announced Thursday.
Federal drug regulators approved Topamax as an anti- epileptic drug and for prevention of migraines. The Justice Department case was the second settlement this week involving a pharmaceutical manufacturer’s promotion of unapproved uses for a drug.
